eligibility_summary
Adults 18–70 with recurrent/metastatic refractory GI cancer (esophageal, gastric, pancreatic, colorectal), target protein+, ECOG 0–1, life ≥3 mo, measurable disease, adequate marrow/organ/coag/renal/liver, residual AEs ≤1, venous access/apheresis feasible, contraception. Exclude: active CNS mets, HIV/HBV/HCV, severe autoimmune/immunosuppression, active infection, unstable CV/organ disease, recent major surgery/therapy, other malignancy, prior CAR‑T/TCR‑T <6 mo, GVHD, systemic steroids, severe allergy, anticoagulation, pregnant/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: BGT007H Injection—an investigational biological, adoptive cellular immunotherapy delivered as a single IV infusion in a modified 3+3 dose escalation (2.0×10^8 to 6.0×10^9 cells). Mechanism of action: Not detailed in the registry. Eligibility requires a positive “target protein” test, indicating BGT007H cells are intended to recognize a predefined tumor-associated antigen and exert antigen-directed immune cytotoxicity against tumor cells. Targets/pathways: Tumor cells from esophageal, gastric, pancreatic, or colorectal cancers that express the target protein, immune effector pathways of cytotoxic lymphocytes (e.g., antigen recognition with downstream perforin/granzyme-mediated killing and cytokine signaling). No additional drugs or combinations are tested.